Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function
Roderick Tan
Summary
This pilot study is testing a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow and tiny blood vessels in transplanted kidneys in very detailed images after kidney transplant surgery. The goal is to see whether changes in the kidney's small blood vessels can help predict how well the transplanted kidney will work early after transplant, including whether delayed graft function may occur. Investigators hope this technique can become a safe, noninvasive way to evaluate transplanted kidneys without needing as many invasive biopsies. It may also help doctors better assess donor kidneys at higher-risk of suboptimal functioning.
Description
Specific Aim 1: Utilize super-resolution ultrasound (SRU) to analyze tiny blood vessels in transplanted kidneys under very detailed imaging and evaluate kidney allografts and predict post-transplantation function. Delayed graft function (DGF) is a common complication that can happen soon after a kidney transplant and may lead to longer recovery times and other health problems. Kidney biopsies are typically required to find the cause, which are invasive procedures. Current imaging tests cannot clearly show the tiny blood vessel changes inside the transplanted kidney that may contribute to the…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: For stage 1 of the study: 1. We will enroll patients ≥18 years of age 2. Patients who received a kidney transplant 2a. Patients requiring dialysis in the first 14 days after transplant 2b. Patients with working allografts not requiring dialysis (control group) For stage 2 of the study 1. We will enroll patients at least 18 years of age or older 2. Patients who received a kidney transplant 2a. Patients who received kidney transplants from low KDPI kidneys (KDPI \< 35) 2b. Patients who received kidney transplants from high KDPI kidneys (KDPI \> 75) Exclusion Criteria: 1…
Interventions
- Diagnostic TestUltrasound contrast agent (Contrast-enhanced ultrasound)
Super-resolution ultrasound using lipid microsphere contrast
- DrugOptison (Perflutren Protein-Type A Microspheres Injectable Suspension)
Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.
- DrugLumason® contrast agent
Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.
- DrugDEFINITY®
Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.
Location
- University of Pittsburgh Medical CenterPittsburgh, Pennsylvania